From: A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma
 | Discovery phase (I) | Test phase (II) | Validation phase (III) | |||||
---|---|---|---|---|---|---|---|---|
PDAC | NC | PDAC | BPD | NC | PDAC | BPD | NC | |
N | 27 | 22 | 100 | 80 | 100 | 70 | 57 | 70 |
Gender | Â | Â | Â | Â | Â | Â | Â | Â |
Male(%) | 19(70.37) | 13(59.09) | 58(58.00) | 46(57.50) | 58(58.00) | 42(60.00) | 36(63.16) | 42(60.00) |
Female(%) | 8(29.63) | 9(40.91) | 42(42.00) | 34(42.50) | 42(42.00) | 28(40.00) | 21(36.84) | 28(40.00) |
Age, year | Â | Â | Â | Â | Â | Â | Â | Â |
Mean ± SD | 59.67 ± 10.71 | 54.91 ± 8.90 | 61.55 ± 11.30 | 50.16 ± 17.50 | 61.64 ± 11.32 | 61.94 ± 10.70 | 49.16 ± 14.71 | 61.46 ± 10.90 |
CA19-9 | Â | Â | Â | Â | Â | Â | Â | Â |
≤ 37 U/mL |  |  | 15(15.00) |  |  | 11(15.71) |  |  |
>37 U/mL | Â | Â | 59(59.00) | Â | Â | 42(60.00) | Â | Â |
Unknown(%) | Â | Â | 26(26.00) | Â | Â | 17(24.29) | Â | Â |
TNM | Â | Â | Â | Â | Â | Â | Â | Â |
I(%) | 5(18.52) | Â | 24(24.00) | Â | Â | 27(38.57) | Â | Â |
II(%) | 11(40.74) | Â | 12(12.00) | Â | Â | 4(5.71) | Â | Â |
III(%) | 2(7.41) | Â | 7(7.00) | Â | Â | 3(4.29) | Â | Â |
IV(%) | 9(33.33) | Â | 47(47.00) | Â | Â | 29(41.43) | Â | Â |
Unknown(%) | Â | Â | 10(10.00) | Â | Â | 7(10.00) | Â | Â |
Lymph node Metastasis | Â | Â | Â | Â | Â | Â | Â | Â |
Yes(%) | 5(18.52) | Â | 20(20.00) | Â | Â | 10(14.29) | Â | Â |
No(%) | 17(62.96) | Â | 68(68.00) | Â | Â | 51(72.86) | Â | Â |
Unknown(%) | 5(18.52) | Â | 12(12.00) | Â | Â | 9(12.86) | Â | Â |
Distant metastasis | Â | Â | Â | Â | Â | Â | Â | Â |
Yes(%) | 7(25.93) | Â | 47(47.00) | Â | Â | 28(40.00) | Â | Â |
No(%) | 20(74.07) | Â | 42(42.00) | Â | Â | 33(47.14) | Â | Â |
Unknown(%) | Â | Â | 11(11.00) | Â | Â | 9(12.86) | Â | Â |